Hemocoagulase might not control but worsen gastrointestinal bleeding in an elderly patient with type II respiratory failure

Qi, Xingshun; Wang, Jigang; Yu, Xianjun; Stefano, Valerio De; Li, Hongyu; Wu, Chunyan; Zeng, Quan; Zhang, Yongguo; Ren, Luping; Hao, Lin; Deng, Jiao; Guo, Xiaozhong

doi:10.21037/tgh.2017.08.08

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many different hemocoagulases according to the source of purified thrombin-like and thromboplastin-like enzymes. The main mechanism of haemostasis is that fibrinogen is cleaved by releasing fibrinopeptide -A or both fibrinopeptide-A and -B, and then fibrin monomer is formed; moreover, activated factor Xa contributes to the formation of thrombin at the site of hemorrhage [1]. Hemocoagulase used in the study was purified from the venom of Chinese Agkistrodon blomhoffii ussurensis living in Changbai Mountain.…”

Section: Introductionmentioning

confidence: 99%

The Effects of Hemocoagulase on Coagulation Factors in an Elderly Patient with Upper Gastrointestinal Hemorrhage: A Case Report

Zhang

2019

CDS

View full text Add to dashboard Cite

Background:Hemocoagulase agkistrodon has been widely used for visceral bleeding, however, its adverse reaction has not been fully recognized.Case Report:A 65-year-old female with upper gastrointestinal hemorrhage occurred severe coagulation disorder during her hospitalization. Transfusion of blood products can not improve coagulation function. Coagulation parameters returned to normal two days after discontinuation of hemocoagulase agkistrodon.Conclusion:So intravenous administration of hemocoagulase should be cautiously used for the treatment of gastrointestinal bleeding.

show abstract

Section: Introductionmentioning

confidence: 99%

The Effects of Hemocoagulase on Coagulation Factors in an Elderly Patient with Upper Gastrointestinal Hemorrhage: A Case Report

Zhang

2019

CDS

View full text Add to dashboard Cite

show abstract

“…Notably, compared with local spray, intravenous infusion can cause hypofibrinogenemia, which may aggravate bleeding. Indeed, this phenomenon has been observed in several case reports [28][29][30].…”

Section: Discussionmentioning

confidence: 59%

No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis

Bai

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background and Aims. Acute upper gastrointestinal bleeding (AUGIB) is one of the most life-threatening emergency conditions. Hemostatic drugs are often prescribed to control AUGIB in clinical practice but have not been recommended by major guidelines and consensus. The aim of this study was to investigate the therapeutic effect of hemostatic drugs on AUGIB in cirrhosis. Methods. All cirrhotic patients with AUGIB who were admitted to our hospital from January 2010 to June 2014 were retrospectively included. Patients were divided into hemostatic drugs and no hemostatic drug groups. A 1 : 1 propensity score matching (PSM) analysis was performed by adjusting age, gender, etiology of liver disease, Child-Pugh score, MELD score, hematemesis, red blood cell transfusion, vasoactive drugs, antibiotics, proton pump inhibitors, and endoscopic variceal therapy. Primary outcomes included 5-day rebleeding and in-hospital mortality. Results. Overall, 982 cirrhotic patients with AUGIB were included (870 in hemostatic drugs group and 112 in no hemostatic drug group). In overall analyses, hemostatic drugs group had a significantly higher 5-day rebleeding rate (18.10% versus 5.40%, P=0.001) than no hemostatic drug group; in-hospital mortality was not significantly different between them (7.10% versus 4.50%, P=0.293). In PSM analyses, 172 patients were included (86 patients in each group). Hemostatic drugs group still had a significantly higher 5-day rebleeding rate (15.10% versus 5.80%, P=0.046); in-hospital mortality remained not significantly different (7.00% versus 3.50%, P=0.304) between them. Statistical results remained in PSM analyses according to the type of hemostatic drugs. Conclusions. The use of hemostatic drugs did not improve the in-hospital outcomes of cirrhotic patients with AUGIB.

show abstract

“…Second, massive blood loss sometimes leads to reactive thrombocytosis [11], thereby resulting in potential hypercoagulability. Third, hemocoagulase is occasionally employed for the treatment of gastrointestinal bleeding, which could reduce fibrinogen concentration [12]. Fourth, blood transfusion is an important treatment of upper gastrointestinal bleeding [13], but the ischemia reperfusion injury of brain cannot be ignored.…”

Section: Strokementioning

confidence: 99%

Stroke and Liver Cirrhosis: A Brief Review of Current Evidence

Zheng¹,

Guo²,

Wang³

et al. 2021

Liver Pathology

Self Cite

View full text Add to dashboard Cite

Stroke and liver cirrhosis are common in our everyday clinical practice, both of which can lead to serious complications. Their association is unclear. In this chapter, we briefly summarized the epidemiology of liver cirrhosis in stroke, reviewed the current evidence regarding the association between liver cirrhosis and stroke, and discussed the potential mechanisms for explaining such an association, such as coagulopathy, hypoperfusion, cardiac diseases, diabetes, and dyslipidemia.

show abstract

Hemocoagulase might not control but worsen gastrointestinal bleeding in an elderly patient with type II respiratory failure

Cited by 5 publications

References 23 publications

The Effects of Hemocoagulase on Coagulation Factors in an Elderly Patient with Upper Gastrointestinal Hemorrhage: A Case Report

The Effects of Hemocoagulase on Coagulation Factors in an Elderly Patient with Upper Gastrointestinal Hemorrhage: A Case Report

No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis

Stroke and Liver Cirrhosis: A Brief Review of Current Evidence

Contact Info

Product

Resources

About